The Indian Journal of Pediatrics

, Volume 86, Issue 6, pp 551–554 | Cite as

Prognostic Significance of IL-6 in Hodgkin Lymphoma

  • Sainath Bhethanabhotla
  • Akash Tiwari
  • M. C. Sharma
  • Sreenivas Vishnubhatla
  • Sameer BakhshiEmail author
Clinical Brief


Elevated serum interleukin-6 (IL-6) in Hodgkin lymphoma (HL) is reported to correlate with B symptoms, response rate and survival in adult patients. The authors studied prognostic significance of IL-6 expression by immunohistochemistry on Hodgkin-Reed Sternberg cells and background reactive cells in a retrospective cohort of pediatric HL patients treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) from January 2009 through December 2013. Of 142 patients, tissue blocks were retrieved in 110 patients. On logistic regression analysis, IL-6 expression on background cells alone was among the factors associated with inferior response rate (OR-9.9, 95%CI-1.2, 78.3; p = 0.03). On multivariate analysis, IL-6 expression on background cells alone had significant impact on 5 y freedom from treatment failure (FFTF) (HR-7.7, 95% CI-1.2, 48.6; p = 0.03). IL-6 expression by immunohistochemistry in the background cells is an independent poor predictor of response and FFTF in pediatric HL. Further prospective studies in children are needed to confirm the current findings and whether IL-6 expression can be used to stratify treatment.


Interleukin-6 Pediatric Hodgkin lymphoma 


Compliance with Ethical Standards

Conflict of Interest



  1. 1.
    Mauz-Körholz C, Metzger ML, Kelly KM, et al. Pediatric hodgkin lymphoma. J Clin Oncol. 2015;33:2975–85.CrossRefGoogle Scholar
  2. 2.
    Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 2004;103:3216–21.CrossRefGoogle Scholar
  3. 3.
    Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19:6812–9.CrossRefGoogle Scholar
  4. 4.
    Casasnovas R-O, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin’s lymphoma: a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2007;25:1732–40.CrossRefGoogle Scholar
  5. 5.
    Reynolds GM, Billingham LJ, Gray LJ, et al. Interleukin 6 expression by Hodgkin/reed-Sternberg cells is associated with the presence of “B” symptoms and failure to achieve complete remission in patients with advanced Hodgkin’s disease. Br J Haematol. 2002;118:195–201.CrossRefGoogle Scholar
  6. 6.
    Bhethanabhotla S, Jain S, Kapoor G, et al. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients. Leuk Lymphoma. 2017;58:1617–23.CrossRefGoogle Scholar
  7. 7.
    Olweny CL. Cotswolds modification of the Ann Arbor staging system for Hodgkin’s disease. J Clin Oncol. 1990;8:1598.CrossRefGoogle Scholar
  8. 8.
    Blay JY, Farcet JP, Lavaud A, Radoux D, Chouaïb S. Serum concentrations of cytokines in patients with Hodgkin’s disease. Eur J Cancer. 1994;30A:321–4.CrossRefGoogle Scholar
  9. 9.
    Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin’s disease. Am J Med. 1997;102:21–8.CrossRefGoogle Scholar
  10. 10.
    Gorschlüter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin’s disease. Ann Oncol. 1995;6:477–82.CrossRefGoogle Scholar
  11. 11.
    Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2019

Authors and Affiliations

  • Sainath Bhethanabhotla
    • 1
    • 2
  • Akash Tiwari
    • 1
    • 2
  • M. C. Sharma
    • 3
  • Sreenivas Vishnubhatla
    • 4
  • Sameer Bakhshi
    • 1
    • 2
    Email author
  1. 1.Department of Medical OncologyAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Dr. B. R. A. Institute Rotary Cancer HospitalAll India Institute of Medical SciencesNew DelhiIndia
  3. 3.Department of PathologyAll India Institute of Medical SciencesNew DelhiIndia
  4. 4.Department of BiostatisticsAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations